Lab
Blue Mountain Diagnostics LLC
Blue Mountain Diagnostics LLC was paid $271K by Medicaid between Dec 2021 and Jul 2024, across 21 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 77% of everything it billed.
33Billing provider infoBLUE MOUNTAIN DIAGNOSTICS LLC
GREENVILLE, SC 29615
GREENVILLE, SC 29615
33aNPI1346847522assigned 10/01/2020
33bProvider typeClinical Medical Laboratory
28Total paid$271K
24GClaims6,352
24DCodes billed21
24AFirst – last monthDec 2021 – Jul 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in South Carolina
Rank by total paid#22 of 39
Median peer was paid$403K
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 224 | $13K | |
| 2022 | 3,586 | $186K | |
| 2023 | 2,131 | $71K | |
| 2024incomplete | 411 | $658.92 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 77% | 2,253 | 764 | $208K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 18% | 2,251 | 761 | $49K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.5% | 18 | 17 | $7K |
| 87481 | 1.0% | 20 | 19 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 154 | 121 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 200 | 170 | $833.12 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 20 | 19 | $556.51 |
| 87500 | <1% | 18 | 18 | $526.10 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 188 | 133 | $494.77 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 43 | 38 | $469.52 |
| 80053 | Comprehensive metabolic panel | <1% | 96 | 84 | $400.26 |
| 80061 | Lipid panel | <1% | 31 | 27 | $181.13 |
9 more codes
| 87653 | <1% | 20 | $130.77 | |
| 87641 | <1% | 18 | $100.36 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32 | $92.14 |
| 87640 | <1% | 18 | $91.23 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 606 | $37.62 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 179 | $22.00 |
| 83037 | 0% | 16 | $0.00 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 158 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALEXANDER, JEFFREY (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Jeffrey P Alexander DDS a Dental Corp | Oakland, CA | $16.38M |
| Jeffrey P Alexander DDS a Dental Corp | Pinole, CA | $11.19M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.